Company news
Creative Medical Technology Holdings, Inc. news in 2023
Creative Medical Technology Holdings, Inc.'s news releases, calls and decks from 2023, newest first.
Creative Medical Technology Holdings (NASDAQ: CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
December 19, 2023
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
October 9, 2023
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
September 18, 2023
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements
June 27, 2023
Creative Medical Technology Announces $2 Million Share Repurchase Program
June 11, 2023
Creative Medical Technology Holdings Announces Reverse Stock Split
June 8, 2023
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform
May 30, 2023
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development
May 21, 2023
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line
May 17, 2023
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study
April 11, 2023
Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update
April 3, 2023
Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes
March 22, 2023
Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development
March 20, 2023
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
March 6, 2023
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes
February 7, 2023